Anterior|Siguiente

Estudio y análisis de la mejora de la necrosis celular miocárdica diabética mediante medicamentos y compuestos chinos

  • role： First author第一作者
  • Affiliation：

    Institute of Basic Medical Sciences of Xiyuan Hospital， China Academy of Chinese Medical Sciences，Beijing 100091，China

  • Email：zying235@163.com
  • Introduction：张莹，在读硕士，从事中药心血管药理研究，E-mail：zying235@163.com
ZHANG Ying,  
  • Affiliation：

    Institute of Basic Medical Sciences of Xiyuan Hospital， China Academy of Chinese Medical Sciences，Beijing 100091，China

XIE Chengzhi,  
  • Affiliation：

    Institute of Basic Medical Sciences of Xiyuan Hospital， China Academy of Chinese Medical Sciences，Beijing 100091，China

FU Chang,  
  • role： Corresponding author通信作者
  • Affiliation：

    Institute of Basic Medical Sciences of Xiyuan Hospital， China Academy of Chinese Medical Sciences，Beijing 100091，China

  • Email：rjx131@sina.com
  • Introduction：任建勋，副研究员，硕士生导师，从事中药心血管疾病的药理研究，E-mail：rjx131@sina.com
REN Jianxun*

resumen

La miocardiopatía diabética (DCM) es una enfermedad microvascular cardíaca causada por la diabetes, que afecta la estructura y la función del corazón, y se considera la principal causa de morbilidad y mortalidad en pacientes diabéticos. La medicina china tiene una rica experiencia clínica y una eficacia precisa en el tratamiento de la DCM, que se caracteriza por múltiples objetivos, múltiples vías, múltiples componentes, efectos secundarios mínimos, que pueden retrasar el desarrollo de la DCM y mejorar los síntomas, y abordar de manera efectiva la complejidad y la longitud del proceso patológico. Numerosos estudios recientes han demostrado que la necrosis celular con la reacción inflamatoria asociada es una de las principales formas de lesión miocárdica en la DCM, lo que promueve el desarrollo de la DCM y está estrechamente relacionada con los cambios en las vías patológicas, el estrés oxidativo, la fibrosis del miocardio, la hipertrofia del miocardio y el deterioro de la función cardíaca. Estos estudios también han proporcionado una base teórica para la exploración de posibles métodos de tratamiento y mecanismos de intervención de la medicina china en el tratamiento de la DCM. El objetivo de este estudio es analizar de manera integral las características de la intervención de medicamentos y compuestos chinos en la necrosis celular miocárdica de la DCM en los últimos años, discutir sus posibles mecanismos y revelar el potencial de los componentes activos y la fórmula terapéutica de la medicina china en la prevención y el tratamiento de la DCM, presentando nuevas ideas y más pruebas experimentales para el uso de la medicina china en el tratamiento de la DCM.

palabra clave

enfermedad cardíaca diabética; necrosis celular miocárdica; medicina china; progreso; mecanismo

References

  1. 1.
    SEFEROVIC P M，PAULUS W J，ROSANO G，et al.Diabetic myocardial disorder.A clinical consensus statement of the heart failure association of the ESC and the ESC working group on myocardial & pericardial diseases［J］.Eur J Heart Fail， 2024，26（9）：1893-1903.
  2. 2.
    TAN Y，ZHANG Z，ZHENG C，et al.Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies： Preclinical and clinical evidence［J］.Nat Rev Cardiol，2020，17（9）：585-607.
  3. 3.
    LU Y，LU Y，MENG J，et al.Pyroptosis and its regulation in diabetic cardiomyopathy［J］.Front Physiol，2021，12：791848.
  4. 4.
    XIE Y，HUANG Y，LING X，et al.Chemerin/CMKLR1 axis promotes inflammation and pyroptosis by activating NLRP3 inflammasome in diabetic cardiomyopathy rat［J］.Front Physiol，2020，11：381.
  5. 5.
    ZHANG J，XIA L，ZHANG F，et al.A novel mechanism of diabetic vascular endothelial dysfunction： Hypoadiponectinemia-induced NLRP3 inflammasome activation［J］.Biochim Biophys Acta Mol Basis Dis，2017，1863 （6）：1556-1567.
  6. 6.
    YU Y F，HU G，ZHOU M L，et al.Chinese medicine intervention in diabetic cardiomyopathy based on autophagy：A review［J］.Chin J Exp Tradit Med Form，2023，29（22）：276-282.
  7. 7.
    BERTHELOOT D，LATZ E，FRANKLIN B S.Necroptosis， pyroptosis and apoptosis：An intricate game of cell death［J］.Cell Mol Immunol，2021，18 （5）：1106-1121.
  8. 8.
    HSU S K，LI C Y，LIN I L，et al.Inflammation-related pyroptosis， a novel programmed cell death pathway， and its crosstalk with immune therapy in cancer treatment［J］.Theranostics，2021，11 （18）：8813-8835.
  9. 9.
    ZHANG S，CHEN Z T，TANG S Y，et al.Relationship between NLRP3 inflammasome and diabetic cardiomyopathy and intervention effect of traditional chinese medicine：A review［J］.Chin J Exp Tradit Med Form，2023，29（16）：250-263.
  10. 10.
    LEE W S，KIM J. Diabetic cardiomyopathy：Where we are and where we are going［J］.Korean J Intern Med，2017，32 （3）：404-421.
  11. 11.
    ZHAO X，ZHANG J，XU F，et al. TAK-242 alleviates diabetic cardiomyopathy via inhibiting pyroptosis and TLR4/CaMKⅡ/NLRP3 pathway［J］.Open Life Sci，2024，19（1）：20220957.
  12. 12.
    WANG Y，FENG W，LI S，et al.Oxycodone attenuates lipopolysaccharide-induced myocardial injury by inhibiting inflammation， oxidation and pyroptosis via Nrf2/HO-1 signalling pathway［J］.Clin Exp Pharmacol Physiol，2024，51 （9）：e13910.
  13. 13.
    WANG F，WANG J，LIANG X，et al.Ghrelin inhibits myocardial pyroptosis in diabetic cardiomyopathy by regulating ERS and NLRP3 inflammasome crosstalk through the PI3K/Akt pathway［J］.J Drug Target，2024，32（2）：148-158.
  14. 14.
    SONG S，GUO R，MEHMOOD A，et al. Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway［J］.CNS Neurosci Ther，2022，28（3）：422-434.
  15. 15.
    CHEN H，TRAN D，YANG H C，et al. Dapagliflozin and ticagrelor have additive effects on the attenuation of the activation of the NLRP3 inflammasome and the progression of diabetic cardiomyopathy：An AMPK-mTOR interplay［J］.Cardiovasc Drugs Ther，2020，34 （4）：443-461.
  16. 16.
    WEI H，BU R，YANG Q，et al.Exendin-4 protects against hyperglycemia-induced cardiomyocyte pyroptosis via the AMPK-TXNIP pathway［J］.J Diabetes Res，2019，2019：8905917.
  17. 17.
    YUAN Q，SUN Y，YANG F，et al. CircRNA DICAR as a novel endogenous regulator for diabetic cardiomyopathy and diabetic pyroptosis of cardiomyocytes［J］.Signal Transduct Target Ther，2023，8 （1）：99.
  18. 18.
    YANG F，QIN Y，LV J，et al. Silencing long non-coding RNA Kcnq1ot1 alleviates pyroptosis and fibrosis in diabetic cardiomyopathy［J］.Cell Death Dis，2018，9 （10）：1000.
  19. 19.
    KONG D Y， KONG X.The role of MicroRNA-129-5p in diabetic cardiomyopathy.［J］.Chin J Gerontol，2021，41（23）：5356-5359.
  20. 20.
    WEI Z，JING Z，PINFANG K，et al.Quercetin inhibits pyroptosis in diabetic cardiomyopathy through the Nrf2 pathway［J］.J Diabetes Res，2022，2022：9723632.
  21. 21.
    GE Z D，LIAN Q，MAO X，et al.Current status and challenges of Nrf2 as a potential therapeutic target for diabetic cardiomyopathy［J］.Int Heart J，2019，60（3）：512-520.
  22. 22.
    YANG W J，CAO J J.Effect of total flavonoids of mulberry leaves on NLRP3 inflammasomes in rats with diabetic cardiomyopathy［J］.Chin J Gerontol，2021，41（23）：5356-5359.
  23. 23.
    SUN S，GONG D，LIU R，et al.Puerarin inhibits NLRP3-Caspase-1-GSDMD-mediated pyroptosis via P2X7 receptor in cardiomyocytes and macrophages［J］.Int J Mol Sci，2023，24 （17）：13169.
  24. 24.
    ZHANG H，ZHANG R X，LIU J C，et al.Formononetin alleviates hyperglycemia-induced cardiomyocyte inflammatory response and pyroptosis by regulating the P2X7R/NLRP3 pathway［J］.Immunol，2020，39（7）：594-600.
  25. 25.
    ZHANG H，CHEN X，ZONG B，et al.Gypenosides improve diabetic cardiomyopathy by inhibiting ROS-mediated NLRP3 inflammasome activation［J］.J Cell Mol Med，2018，22 （9）：4437-4448.
  26. 26.
    YANG Z L，XU H L，CHENG Y，et al.Effect of ursolic acid on cardiomyopathy of mice with diabetes and its mechanism［J］.Chin J Appl Physiol，2018，34（4）：309-312 339.
  27. 27.
    LIANG R K，ZHAO Y Y，SHI M L，et al.Skimmin protects diabetic cardiomyopathy in streptozotocin-induced diabetic rats［J］.Kaohsiung J Med Sci，2021，37（2）：136-144.
  28. 28.
    WEN Y，GENG L，ZHOU L，et al.Betulin alleviates on myocardial inflammation in diabetes mice via regulating Siti1/NLRP3/NF-κB pathway［J］.Int Immunopharmacol，2020，85：106653.
  29. 29.
    ZHU Y W. The protective effect and mechanism of geniposide on myocardial injury in type 1 diabetes［D］.Shanghai：Shanghai Ocean University，2021.
  30. 30.
    ZHU M H，LI Z W，CHEN X L，et al.The protective effect of sapindoside from Sapindus mukorossi Gaertn.on H9C2 cardiomyocyte injury induced by high glucose［J］.Asia-Pacific Tradit Med，2019，15（12）：9-12.
  31. 31.
    QU X F，ZHAI B Z，HU W L，et al. Pyrroloquinoline quinone ameliorates diabetic cardiomyopathy by inhibiting the pyroptosis signaling pathway in C57BL/6 mice and AC16 cells［J］.Eur J Nutr，2022，61 （4）：1823-1836.
  32. 32.
    YOU L，YANG C，DU Y，et al. A systematic review of the pharmacology， toxicology and pharmacokinetics of matrine［J］.Front Pharmacol，2020，11：01067.
  33. 33.
    YANG L，CHENG C F，LI Z F，et al.Berberine blocks inflammasome activation and alleviates diabetic cardiomyopathy via the miR‑18a‑3p/Gsdmd pathway［J］.Int J Mol Med，2023，51 （6）：49.
  34. 34.
    ZHONG C，XIE Y，WANG H，et al.Berberine inhibits NLRP3 inflammasome activation by regulating mTOR/mtROS axis to alleviate diabetic cardiomyopathy［J］.Eur J Pharmacol，2024，964：176253.
  35. 35.
    SUN X，DUAN J，GONG C，et al. Colchicine ameliorates dilated cardiomyopathy via SIRT2-mmediated suppression of NLRP3 inflammasome activation［J］.J Am Heart Assoc，2022，11（13）：e025266.
  36. 36.
    WU YJ， WU WY， LI Y， et al. Effect of cryptotanshinone on hyperglycemic-induced pyroptosis of cardiomyocytes by regulating TLR4/NF-κB/NLRP3 signaling pathway［J］.Chin J Integr Med Cardio-Cerebrovasc Dis，2024，22（14）：2553-2558.
  37. 37.
    WEI Z，PINFANG K，JING Z，et al.Curcumin improves diabetic cardiomyopathy by inhibiting pyroptosis through Akt/Nrf2/ARE pathway［J］.Mediators Inflamm，2023，2023：3906043.
  38. 38.
    HU Y，ZHANG S，LOU H，et al.Aloe-emodin derivative， an anthraquinone compound， attenuates pyroptosis by targeting NLRP3 inflammasome in diabetic cardiomyopathy［J］.Pharmaceuticals （Basel），2023，16（9）：1275.
  39. 39.
    ABO-SAIF M A，RAGAB A E，IBRAHIM A O，et al. Pomegranate peel extract protects against the development of diabetic cardiomyopathy in rats by inhibiting pyroptosis and downregulating LncRNA-MALAT1［J］.Front Pharmacol，2023，14：1166653.
  40. 40.
    LI H，SHI Y，WANG X，et al.Piceatannol alleviates inflammation and oxidative stress via modulation of the Nrf2/HO-1 and NF-κB pathways in diabetic cardiomyopathy［J］.Chem Biol Interact，2019，310：108754.
  41. 41.
    DING P，YE Z M，LIU B，et al.Effect of protocatechualdehyde on streptozotocin induced diabetic cardiomyopathy in mice［J］.Mod Food Sci Technol，2023，40（3）：1-7.
  42. 42.
    GAO J P.Distribution of traditional Chinease medicine syndrome differentiation of diabetic cardiomyopathy［D］. Dalian：Dalian Medical University，2017.
  43. 43.
    LI J Y，ZHAO C C，PENG J F，et al.The protective effect of Shengmaiyin on diabetic cardiomyopathy via NLRP3/Caspase-1 pathway［J］.Evid Based Complement Alternat Med，2022，2022：1234434.
  44. 44.
    YAN M，LI L，WANG Q，et al.The Chinese herbal medicine Fufang Zhenzhu Tiaozhi protects against diabetic cardiomyopathy by alleviating cardiac lipotoxicity-induced oxidative stress and NLRP3-dependent inflammasome activation［J］.Biomed Pharmacother，2022，148：112709.
  45. 45.
    ZHANG Y N，DING Y J，XU H Z，et al.Effect of modified Taohe Chengqitang on NLRP3 inflammasomes in rats with diabetic cardiomyopathy［J］.Chin J Exp Tradit Med Form，2022，28（16）：59-65.
  46. 46.
    YAO R，CAO Y，WANG C，et al.Taohuajing reduces oxidative stress and inflammation in diabetic cardiomyopathy through the sirtuin 1/nucleotide-binding oligomerization domain-like receptor protein 3 pathway［J］.BMC Complement Med Ther，2021，21（1）：78.
  47. 47.
    RUAN N B，LI J J，XU Q，et al.Effects of Danzhi Jiangtang capsules on myocardial injury of db/db mice based on NLRP3 inflammasome-mediated pyroptosis［J］.Chin Pharmacol Bull，2024，doi：.
  48. 48.
    YANG P，LIU T H，QIN L L，et al.Improvement of diabetic cardiomyopathy by Chinese medicine based on TGF-β/Smad pathway：A review［J］.Chin J Exp Tradit Med Form，2023，29（1）：215-226.

Leer el texto completo

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website